My Portfolio
+
LINK YOUR PORTFOLIO

Fulcrum Therapeutics Inc FULC:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 06/02/26 EDT
3.22quote price arrow up+0.08 (+2.55%)
Volume
5,503,064
52 week range
2.83 - 15.74
Loading...
  • Open3.11
  • Day High3.27
  • Day Low3.09
  • Prev Close3.22
  • 52 Week High15.74
  • 52 Week High Date12/08/25
  • 52 Week Low2.83
  • 52 Week Low Date06/02/26

Latest On Fulcrum Therapeutics Inc

 

Key Stats

  • Market Cap214.559M
  • Shares Out66.63M
  • 10 Day Average Volume3.91M
  • Dividend-
  • Dividend Yield-
  • Beta2.92

Latest On Fulcrum Therapeutics Inc

 

KEY STATS

  • Open3.11
  • Day High3.27
  • Day Low3.09
  • Prev Close3.22
  • 52 Week High15.74
  • 52 Week High Date12/08/25
  • 52 Week Low2.83
  • 52 Week Low Date06/02/26
  • Market Cap214.559M
  • Shares Out66.63M
  • 10 Day Average Volume3.91M
  • Dividend-
  • Dividend Yield-
  • Beta2.92

RATIOS/PROFITABILITY

  • EPS (TTM)-1.15
  • P/E (TTM)-2.81
  • Fwd P/E (NTM)-2.81
  • EBITDA (TTM)-85.034M
  • ROE (TTM)-27.10%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-0.64%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date07/27/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses technology to identify drug targets that can modulate gene expression to treat the...
Kate Haviland
Independent Chairman of the Board
Alex Sapir
President, Chief Executive Officer, Director
Alan Musso CPA
Chief Financial Officer, Treasurer
Address
26 Landsdowne Street
Cambridge, MA
02139
United States